Dr. Daud Discusses the Current Status of Immunotherapy in Melanoma

Adil Daud, MD
Published: Monday, Aug 28, 2017



Adil Daud, MD, clinical professor, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, at University of California, San Francisco, discusses the current status of immunotherapy in melanoma.

Immunotherapy is at a very exciting point in melanoma, says Daud. Specifically, there were a number of combinations presented at the 2017 ASCO Annual Meeting for the relapse/refractory population that showed responses.
 
SELECTED
LANGUAGE


Adil Daud, MD, clinical professor, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, at University of California, San Francisco, discusses the current status of immunotherapy in melanoma.

Immunotherapy is at a very exciting point in melanoma, says Daud. Specifically, there were a number of combinations presented at the 2017 ASCO Annual Meeting for the relapse/refractory population that showed responses.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication
x